6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH
Reports Second Quarter 2025 Financial Results and Corporate Updates
News, Securities Holder Rights or Indentures, Material Contracts
Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Shareholder votes
Reports First Quarter 2025 Financial Results and Corporate Updates
Enters into Agreement to Sell Priority Review Voucher for $155 Million
Investor Presentation
FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities